A world-first trial of a next-generation cancer treatment which uses a tailored does of radioactive copper to target tumours is underway at Royal North Shore Hospital (RNSH). This new treatment approach had been developed in conjunction with Sydney Vital and Clarity Pharmaceuticals.
Sydney Vital Flagship Program 1 is currently looking to hire a Research Fellow.
Sydney Vital Research Scholar Awards Round 9
Sydney Vital is pleased to invite our members to apply for our Research Scholarship Awards, Round 8.
Sydney Vital is pleased to invite applications for its Seed Funding Awards to the value of $50,000 each. The Sydney Vital Seed Funding Scheme intends to seed new ideas, with the goal of generating data to a point where external funding may be sought.
A team of international collaborators under Sydney Vital’s Flagship 2, has won the 2nd prize in the 2nd International-Atom Indonesia Best Paper Awards 2018 (I-AIBPA 2018)
The Latest Developments in Immunotherapy – Basic Science, Transalational and Clinical: Immuno-Oncology Symposium
On Thursday, 29th November, Sydney Vital hosted an Immuno-Oncology Symposium, which aims at bringing up the Latest Developments in Immunotherapy- Basic Science, Translational and Clinical.
Ms Grace Lim, the PhD student under our Thyroid Cancer TCE (Translational Centre of Excellence), was awarded a Sydney Vital Travel Grant to attend and present her research study at this year’s annual meeting of the American Thyroid Association.
On Thursday, 9th November, we were proud to present our second Thyroid Cancer Interest Group this year with our sponsor- Eisai Australia.